Skip to main content
. 2020 Jun 21;12(6):1845. doi: 10.3390/nu12061845

Table 4.

Non-amino acid variables of the population of patients with Alzheimer’s disease (AD) subdivided into malnourished patients (MNA Group 1), patients at risk of malnutrition (MNA Group 2), normonourished patients (MNA Group 3), and combined group (CG = MNA Group 1 + MNA Group 2).

Variable CG
(N = 26)
MNA Grp 1
(N = 8)
MNA Grp 2
(N = 18)
MNA Grp 3
(N = 28)
p Value CG vs. Grp 3
Demographic variables
Age (years) 74.58 ± 9.01 75.38 ± 5.42 74.22 ± 10.33 74.32 ± 7.11 0.81
Male gender (%) 17 (65%) 5 (62%) 12 (67%) 20 (71%) 0.07
Anthropometric variables
Education (years) 7.11 ± 4.08 8.33 ± 4.59 6.54 ± 3.89 7.41 ± 3.75 0.84
Body weight (kg) 59.15 ± 11.46 55.70 ± 13.42 60.68 ± 10.52 68.11 ± 12.83 0.006
Height (cm) 158.42 ± 10.82 162.00 ± 8.64 156.83 ± 11.52 163.14 ± 8.66 0.10
Body mass index (kg/m2) 23.76 ± 5.00 21.58 ± 6.52 24.73 ± 4.00 25.60 ± 4.49 0.09
Mid-arm circumference (cm) 25.56 ± 3.24 23.44 ± 3.83 26.50 ± 2.53 26.43 ± 2.36 0.34
Biohumoral variables
Glucose (NV 70–115 mg/dL) 85.50 ± 9.74 86.00 ± 5.93 85.28 ± 11.18 90.36 ± 14.56 0.36
Insulin (NV 4–24 µU/mL) 11.10 ± 4.37 9.89 ± 3.37 11.64 ± 4.73 13.52 ± 5.53 0.11
HOMA-IR (NV < 2.4) 3.41 ± 1.99 2.55 ± 1.07 3.79 ± 2.21 4.07 ± 1.89 0.15
Glycosylated haemoglobin (4.8–5.9%) 5.53 ± 0.51 5.58 ± 0.21 5.52 ± 0.60 5.61 ± 0.88 0.69
Total cholesterol (NV < 200 mg/dL) 188.77 ± 32.44 196.50 ± 36.26 185.33 ± 31.08 186.04 ± 32.87 0.96
HDL cholesterol (NV: M > 55 mg/dL; F > 65 mg/dL) 56.85 ± 17.72 52.88 ± 12.53 58.61 ± 19.66 53.68 ± 14.05 0.71
LDL cholesterol (NV < 100 mg/dL) 111.69 ± 25.28 123.25 ± 23.43 106.56 ± 24.96 110.25 ± 26.96 0.89
Transferrin (NV 200–360 mg/dL) 230.69 ± 33.89 220.25 ± 40.08 235.33 ± 30.88 229.07 ± 41.89 0.72
Iron (NV 59–158 µg/dL) 86.38 ± 29.37 91.13 ± 26.63 84.28 ± 31.01 83.43 ± 22.24 0.72
Tryglycerides (NV 0–200 mg/dL) 99.00 ± 34.58 100.13 ± 45.82 98.50 ± 29.89 105.36 ± 43.55 0.94
Vitamin B12 (NV 191–663 pg/mL) 331.96 ± 139.31 446.88 ± 150.31 277.88 ± 97.56 318.00 ± 162.25 0.47
Folate (NV 3.1–17.5 ng/mL) 6.47 ± 3.49 6.21 ± 3.66 6.59 ± 3.52 6.64 ± 2.93 0.49
Creatinine (NV: M 0.73–1.18 mg/dL; F 0.55–1.02 mg/dL) 0.90 ± 0.24 0.97 ± 0.33 0.86 ± 0.18 0.91 ± 0.21 0.66
Total proteins (NV 6.6–8.7 g/dL) 6.33 ± 0.49 6.29 ± 0.79 6.35 ± 0.30 6.27 ± 0.33 0.79
Albumin (NV 3500–5200 mg/dL) 3683.85 ± 360.31 3572.50 ± 560.91 3733.33 ± 230.09 3728.93 ± 284.84 0.54
White blood cell count (NV 4.00–10.00 × 103/µL) 6.59 ± 1.79 7.16 ± 2.12 6.32 ± 1.61 6.11 ± 1.21 0.60
Red blood cell count (NV: M 4.30–5.70 × 106/µL; F 3.80–5.20 × 106/µL) 4.20 ± 0.46 4.21 ± 0.41 4.19 ± 0.50 4.47 ± 0.44 0.025
Haemoglobin (NV: M 13.2–17.3 g/dL; F 11.7–15.5 g/dL) 12.81 ± 1.31 12.70 ± 0.95 12.86 ± 1.47 13.44 ± 1.18 0.035
Erythrosedimentation rate (NV < 15 mm/1st h) 23.28 ± 22.19 24.25 ± 24.67 22.82 ± 21.71 13.00 ± 12.16 0.07
AD biomarkers in CSF
tau (NV < 404 pg/mL) 486.86 ± 609.36 231.60 ± 107.46 628.67 ± 730.94 444.14 ± 216.02 0.14
p-tau (NV < 56.5 pg/mL) 72.07 ± 44.15 45.60 ± 20.13 86.78 ± 47.78 79.20 ± 28.62 0.28
β-amyloid (NV > 599 pg/mL) 532.29 ± 471.59 343.60 ± 172.28 637.11 ± 558.52 566.95 ± 283.63 0.18
β-amyloid/tau (NV > 1.6) 2.46 ± 3.43 1.94 ± 1.35 2.74 ± 4.23 2.02 ± 2.31 0.96
β-amyloid/p-tau (NV > 11.5) 9.92 ± 10.33 9.52 ± 7.52 10.14 ± 12.04 8.33 ± 6.32 0.99
Neurocognitive tests
Mini Mental State Examination (MMSE < 24 denotes cognitive impairment) 15.75 ± 7.30 17.17 ± 5.75 15.11 ± 8.07 19.14 ± 7.13 0.20
Digit span (NV < 3.75) 4.06 ± 0.77 4.92 ± 0.52 3.63 ± 0.41 3.78 ± 1.00 0.52
Trail Making Test TMT-A (NV < 93″) 162.00 ± 56.19 178.00 ± 33.94 155.60 ± 65.34 145.21 ± 55.31 0.65
Trail Making Test TMT-B (NV < 282″) 262.00 ± 136.96 347.00 ± 0.00 219.50 ± 163.34 162.33 ± 94.98 0.24

Data are expressed as mean ± standard deviation except for gender, expressed as N (%). Reported p values are for between-group comparison (CG vs. MNA Group 3, Kruskal–Wallis test). Abbreviations: MNA, Mini Nutritional Assessment; NV, normal values; HOMA-IR, HOmeostasis Model Assessment-Insulin Resistance; CSF, cerebrospinal fluid.